<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0003003'>Colon cancer</z:hpo> screening with colonoscopy is an accepted strategy; however, there are limited data regarding the cost-effectiveness of screening for <z:e sem="disease" ids="C0814138" disease_type="Neoplastic Process" abbrv="">upper GI cancers</z:e> (esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> with its premalignant precursor <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, esophageal <z:e sem="disease" ids="C0007137,C0751688" disease_type="Neoplastic Process" abbrv="">squamous cell cancer</z:e>, <z:mp ids='MP_0008010'>gastric adenocarcinoma</z:mp>) in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To evaluate the cost-effectiveness of screening the general population for <z:e sem="disease" ids="C0814138" disease_type="Neoplastic Process" abbrv="">upper GI cancers</z:e> by performing an upper endoscopy at the time of screening colonoscopy </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: Decision analysis </plain></SENT>
<SENT sid="3" pm="."><plain>SETTING: Third-party-payer perspective with a time horizon of 30 years or until <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS: This study involved 50-year-old patients already undergoing screening colonoscopy </plain></SENT>
<SENT sid="5" pm="."><plain>INTERVENTION: Comparison of two strategies: performing and not performing a screening upper endoscopy at the time of screening colonoscopy </plain></SENT>
<SENT sid="6" pm="."><plain>MAIN OUTCOME MEASUREMENTS: Incremental cost-effectiveness ratio (ICER) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: One-time screening for the general population at the age of 50 for <z:e sem="disease" ids="C0814138" disease_type="Neoplastic Process" abbrv="">upper GI cancers</z:e> required $115,664 per quality-adjusted life year (QALY) compared with no screening or surveillance </plain></SENT>
<SENT sid="8" pm="."><plain>A strategy of screening and surveillance for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> required only $95,559 per QALY saved </plain></SENT>
<SENT sid="9" pm="."><plain>In 1-way sensitivity analyses, the prevalence rates of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, esophageal <z:e sem="disease" ids="C0007137,C0751688" disease_type="Neoplastic Process" abbrv="">squamous cell cancer</z:e>, or <z:mp ids='MP_0008010'>gastric adenocarcinoma</z:mp> would have to increase by 654%, 1948%, and 337%, respectively, to generate an ICER of less than $50,000 per QALY </plain></SENT>
<SENT sid="10" pm="."><plain>LIMITATIONS: Omission of <z:e sem="disease" ids="C0032927" disease_type="Neoplastic Process" abbrv="">premalignant conditions</z:e> for <z:e sem="disease" ids="C0007137,C0751688" disease_type="Neoplastic Process" abbrv="">squamous cell cancer</z:e> and <z:mp ids='MP_0008010'>gastric adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The ICER for screening the general population for <z:e sem="disease" ids="C0814138" disease_type="Neoplastic Process" abbrv="">upper GI cancers</z:e> with endoscopy remains high, despite accounting for reduced endoscopy costs and the combined benefits of detecting early esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, esophageal <z:e sem="disease" ids="C0007137,C0751688" disease_type="Neoplastic Process" abbrv="">squamous cell cancer</z:e>, and <z:mp ids='MP_0008010'>gastric adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>However, the ICER compares favorably with commonly performed screening strategies for other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>